

4. (Amended) A peptide according to claim 1[, 2 or 3,] when obtained by a synthetic process.
19. (Amended) The use of a peptide according to [any one of claims 1 to 8,] claim 1 in the manufacture of a medicament for the treatment of chronic disorders of the central nervous system.
20. (Amended) The use of a peptide according to [any one of claims 1 to 8] claim 1 in the manufacture of a medicament for the treatment of chronic disorders of the immune system.
21. (Amended) A method of treating disorders of the central nervous system and/or of the immune system, comprising administering a therapeutically effective amount of a peptide according to [any one of claims 1 to 8] claim 1 to a patient.
22. (Amended) A composition comprising a peptide according to [any one of claims 1 to 8,] claim 1 in combination with a physiologically acceptable carrier.
23. (Amended) A composition comprising two or more peptides according to [any one of claims 1 to 8,] claim 1 in combination with a physiologically acceptable carrier.
24. (Amended) A composition according to claim 22 [or 23,] in a form suitable for injection.
25. (Amended) A composition according to claim 22 [or 23,] in a form suitable for absorption through the mucosa of the oral/nasopharyngeal cavity and/or in a form suitable for absorption in the alimentary canal.
26. (Amended) A composition according to claim 22 [or 23,] in the form of a tablet, lozenge, gel, patch or plaster.

27. (Amended) A composition according to claim 22 [or 23,] in a form suitable for topical application.

28. (Amended) The use of a peptide according to [any one of claims 1 to 8] claim 1 as a dietary supplement.

29. (Amended) The use of a peptide according to [any one of claims 1 to 8] claim 1 as a dietary supplement for babies, small children, adults who have been subjected to chemotherapy and/or adults who have suffered from [cahexia] cachexia, or weight loss due to chronic disease.

30. (Amended) A dietary supplement comprising an orally ingestible combination of a peptide according to [any one of claims 1 to 8] claim 1 combination with a physiologically acceptable.

31. (Amended) An antibody which binds to a peptide according to [any one of claims 1 or 8] claim 1.

32. (Amended) An antibody obtainable by using a peptide according to [any one of claims 1 to 8] claim 1 as an antigen.